Feiran Lou1, Camelia S Sima2, Valerie W Rusch3, David R Jones3, James Huang4. 1. Department of Surgery, SUNY Downstate Medical Center, Brooklyn, New York. 2. Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: huangj@mskcc.org.
Abstract
BACKGROUND: The benefits of screening for non-small cell lung cancer (NSCLC) have been established for high-risk individuals, and recent guidelines advocate continued surveillance after curative therapy. Yet the optimal posttreatment surveillance strategy remains to be determined. We compared patterns of recurrence and modes of detection in surgically treated patients with pathologic early-stage and locally advanced NSCLC. METHODS: Consecutive patients who had undergone resection for stage I-IIIA NSCLC from 2004 to 2009 were identified from a prospectively maintained institutional database. All patients received interval chest computed tomography (CT) scans every 6 to 12 months after treatment. RESULTS: In total, 1,640 patients were identified: 181 of 346 patients with stage IIIA NSCLC (52%) and 257 of 1,294 patients with stage I-II NSCLC (20%) experienced recurrences. Surveillance CT detected asymptomatic recurrences in 157 stage I-II patients (61%) and 89 stage IIIA patients (49%) (p=0.045). Symptoms led to detection of recurrences more often in stage IIIA patients (73, 40%) than in stage I-II patients (81, 32%). Distant recurrences were more common in stage IIIA patients than in stage I-II patients (153, 85%, vs 190, 74%; p=0.01). In stage IIIA patients, the risk of recurrence was highest during the first 2 years after operation, but it remained substantial into year 4. CONCLUSIONS: Stage IIIA patients had fewer recurrences detected by surveillance CT, a higher rate of symptomatic presentation, a markedly higher risk of recurrence, and a higher propensity for distant recurrence. Surveillance strategies may need to account for stage-specific differences.
BACKGROUND: The benefits of screening for non-small cell lung cancer (NSCLC) have been established for high-risk individuals, and recent guidelines advocate continued surveillance after curative therapy. Yet the optimal posttreatment surveillance strategy remains to be determined. We compared patterns of recurrence and modes of detection in surgically treated patients with pathologic early-stage and locally advanced NSCLC. METHODS: Consecutive patients who had undergone resection for stage I-IIIA NSCLC from 2004 to 2009 were identified from a prospectively maintained institutional database. All patients received interval chest computed tomography (CT) scans every 6 to 12 months after treatment. RESULTS: In total, 1,640 patients were identified: 181 of 346 patients with stage IIIA NSCLC (52%) and 257 of 1,294 patients with stage I-II NSCLC (20%) experienced recurrences. Surveillance CT detected asymptomatic recurrences in 157 stage I-II patients (61%) and 89 stage IIIA patients (49%) (p=0.045). Symptoms led to detection of recurrences more often in stage IIIA patients (73, 40%) than in stage I-II patients (81, 32%). Distant recurrences were more common in stage IIIA patients than in stage I-II patients (153, 85%, vs 190, 74%; p=0.01). In stage IIIA patients, the risk of recurrence was highest during the first 2 years after operation, but it remained substantial into year 4. CONCLUSIONS: Stage IIIA patients had fewer recurrences detected by surveillance CT, a higher rate of symptomatic presentation, a markedly higher risk of recurrence, and a higher propensity for distant recurrence. Surveillance strategies may need to account for stage-specific differences.
Authors: Hiroshi Sugimura; Francis C Nichols; Ping Yang; Mark S Allen; Stephen D Cassivi; Claude Deschamps; Brent A Williams; Peter C Pairolero Journal: Ann Thorac Surg Date: 2007-02 Impact factor: 4.330
Authors: V Westeel; M P Lebitasy; M Mercier; P Girard; F Barlesi; F Blanchon; J Tredaniel; P Bonnette; M C Woronoff-Lemsi; J L Breton; R Azarian; P E Falcoz; S Friard; L Geriniere; S Laporte; E Lemarie; E Quoix; G Zalcman; J Guigay; F Morin; B Milleron; A Depierre Journal: Rev Mal Respir Date: 2007-05 Impact factor: 0.622
Authors: Francine L Jacobson; John H M Austin; John K Field; James R Jett; Shaf Keshavjee; Heber MacMahon; James L Mulshine; Reginald F Munden; Ravi Salgia; Gary M Strauss; David J Sugarbaker; Scott J Swanson; William D Travis; Michael T Jaklitsch Journal: J Thorac Cardiovasc Surg Date: 2012-07 Impact factor: 5.209
Authors: Yanding Zhao; Frederick S Varn; Guoshuai Cai; Feifei Xiao; Christopher I Amos; Chao Cheng Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-15 Impact factor: 4.254
Authors: Melisa L Wong; Timothy L McMurry; George J Stukenborg; Amanda B Francescatti; Carla Amato-Martz; Jessica R Schumacher; George J Chang; Caprice C Greenberg; David P Winchester; Daniel P McKellar; Louise C Walter; Benjamin D Kozower Journal: Lung Cancer Date: 2016-11-09 Impact factor: 5.705
Authors: Andrea Billè; Usman Ahmad; Kaitlin M Woo; Kei Suzuki; Prasad Adusumilli; James Huang; David R Jones; Nabil Pierre Rizk Journal: Ann Thorac Surg Date: 2016-06-24 Impact factor: 4.330
Authors: Hideki Ujiie; Kyuichi Kadota; Jamie E Chaft; Daniel Buitrago; Camelia S Sima; Ming-Ching Lee; James Huang; William D Travis; Nabil P Rizk; Charles M Rudin; David R Jones; Prasad S Adusumilli Journal: J Clin Oncol Date: 2015-08-10 Impact factor: 44.544
Authors: Adam R Belanger; Johnathan Hollyfield; Gabriella Yacovone; Agathe S Ceppe; Jason A Akulian; A Cole Burks; M Patricia Rivera; Leslie G Dodd; Jason M Long; Benjamin E Haithcock; Chad V Pecot Journal: J Thorac Dis Date: 2019-08 Impact factor: 2.895
Authors: Joel W Neal; Daniel B Costa; Alona Muzikansky; Joseph B Shrager; Michael Lanuti; James Huang; Kavitha J Ramachandran; Deepa Rangachari; Mark S Huberman; Zofia Piotrowska; Mark G Kris; Christopher G Azzoli; Lecia V Sequist; Jamie E Chaft Journal: JCO Precis Oncol Date: 2021-02-01